Exploring the complexity and spectrum of racial/ethnic disparities in colon cancer management.


Journal

International journal for equity in health
ISSN: 1475-9276
Titre abrégé: Int J Equity Health
Pays: England
ID NLM: 101147692

Informations de publication

Date de publication:
14 04 2023
Historique:
received: 18 09 2022
accepted: 04 04 2023
medline: 18 4 2023
entrez: 14 4 2023
pubmed: 15 4 2023
Statut: epublish

Résumé

Colorectal cancer is a leading cause of morbidity and mortality across U.S. racial/ethnic groups. Existing studies often focus on a particular race/ethnicity or single domain within the care continuum. Granular exploration of disparities among different racial/ethnic groups across the entire colon cancer care continuum is needed. We aimed to characterize differences in colon cancer outcomes by race/ethnicity across each stage of the care continuum. We used the 2010-2017 National Cancer Database to examine differences in outcomes by race/ethnicity across six domains: clinical stage at presentation; timing of surgery; access to minimally invasive surgery; post-operative outcomes; utilization of chemotherapy; and cumulative incidence of death. Analysis was via multivariable logistic or median regression, with select demographics, hospital factors, and treatment details as covariates. 326,003 patients (49.6% female, 24.0% non-White, including 12.7% Black, 6.1% Hispanic/Spanish, 1.3% East Asian, 0.9% Southeast Asian, 0.4% South Asian, 0.3% AIAE, and 0.2% NHOPI) met inclusion criteria. Relative to non-Hispanic White patients: Southeast Asian (OR 1.39, p < 0.01), Hispanic/Spanish (OR 1.11 p < 0.01), and Black (OR 1.09, p < 0.01) patients had increased odds of presenting with advanced clinical stage. Southeast Asian (OR 1.37, p < 0.01), East Asian (OR 1.27, p = 0.05), Hispanic/Spanish (OR 1.05 p = 0.02), and Black (OR 1.05, p < 0.01) patients had increased odds of advanced pathologic stage. Black patients had increased odds of experiencing a surgical delay (OR 1.33, p < 0.01); receiving non-robotic surgery (OR 1.12, p < 0.01); having post-surgical complications (OR 1.29, p < 0.01); initiating chemotherapy more than 90 days post-surgery (OR 1.24, p < 0.01); and omitting chemotherapy altogether (OR 1.12, p = 0.05). Black patients had significantly higher cumulative incidence of death at every pathologic stage relative to non-Hispanic White patients when adjusting for non-modifiable patient factors (p < 0.05, all stages), but these differences were no longer statistically significant when also adjusting for modifiable factors such as insurance status and income. Non-White patients disproportionately experience advanced stage at presentation. Disparities for Black patients are seen across the entire colon cancer care continuum. Targeted interventions may be appropriate for some groups; however, major system-level transformation is needed to address disparities experienced by Black patients.

Sections du résumé

BACKGROUND
Colorectal cancer is a leading cause of morbidity and mortality across U.S. racial/ethnic groups. Existing studies often focus on a particular race/ethnicity or single domain within the care continuum. Granular exploration of disparities among different racial/ethnic groups across the entire colon cancer care continuum is needed. We aimed to characterize differences in colon cancer outcomes by race/ethnicity across each stage of the care continuum.
METHODS
We used the 2010-2017 National Cancer Database to examine differences in outcomes by race/ethnicity across six domains: clinical stage at presentation; timing of surgery; access to minimally invasive surgery; post-operative outcomes; utilization of chemotherapy; and cumulative incidence of death. Analysis was via multivariable logistic or median regression, with select demographics, hospital factors, and treatment details as covariates.
RESULTS
326,003 patients (49.6% female, 24.0% non-White, including 12.7% Black, 6.1% Hispanic/Spanish, 1.3% East Asian, 0.9% Southeast Asian, 0.4% South Asian, 0.3% AIAE, and 0.2% NHOPI) met inclusion criteria. Relative to non-Hispanic White patients: Southeast Asian (OR 1.39, p < 0.01), Hispanic/Spanish (OR 1.11 p < 0.01), and Black (OR 1.09, p < 0.01) patients had increased odds of presenting with advanced clinical stage. Southeast Asian (OR 1.37, p < 0.01), East Asian (OR 1.27, p = 0.05), Hispanic/Spanish (OR 1.05 p = 0.02), and Black (OR 1.05, p < 0.01) patients had increased odds of advanced pathologic stage. Black patients had increased odds of experiencing a surgical delay (OR 1.33, p < 0.01); receiving non-robotic surgery (OR 1.12, p < 0.01); having post-surgical complications (OR 1.29, p < 0.01); initiating chemotherapy more than 90 days post-surgery (OR 1.24, p < 0.01); and omitting chemotherapy altogether (OR 1.12, p = 0.05). Black patients had significantly higher cumulative incidence of death at every pathologic stage relative to non-Hispanic White patients when adjusting for non-modifiable patient factors (p < 0.05, all stages), but these differences were no longer statistically significant when also adjusting for modifiable factors such as insurance status and income.
CONCLUSIONS
Non-White patients disproportionately experience advanced stage at presentation. Disparities for Black patients are seen across the entire colon cancer care continuum. Targeted interventions may be appropriate for some groups; however, major system-level transformation is needed to address disparities experienced by Black patients.

Identifiants

pubmed: 37060065
doi: 10.1186/s12939-023-01883-w
pii: 10.1186/s12939-023-01883-w
pmc: PMC10105474
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

68

Subventions

Organisme : NCI NIH HHS
ID : T32 CA251070
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Ann Surg Oncol. 2015 Sep;22(9):2902-11
pubmed: 25652051
Am J Cardiol. 2017 Apr 15;119(8):1127-1134
pubmed: 28237284
J Gastrointest Oncol. 2016 Apr;7(Suppl 1):S32-43
pubmed: 27034811
Gynecol Oncol. 2014 May;133(2):238-41
pubmed: 24613675
Breast Cancer Res Treat. 2013 Oct;141(3):461-70
pubmed: 24062208
J Gen Intern Med. 2015 Aug;30 Suppl 3:S568-75
pubmed: 26105670
Am J Prev Med. 2014 Mar;46(3):228-36
pubmed: 24512861
J Community Health. 2017 Oct;42(5):1044-1061
pubmed: 28439739
J Clin Gastroenterol. 2020 Sep;54(8):714-719
pubmed: 32520886
N Engl J Med. 2007 Sep 20;357(12):1221-8
pubmed: 17881753
Br J Cancer. 2009 Dec 3;101 Suppl 2:S92-S101
pubmed: 19956172
JAMA Intern Med. 2020 Mar 1;180(3):463-466
pubmed: 31841583
Int J Equity Health. 2015 Oct 29;14:109
pubmed: 26511360
J Cancer Educ. 2010 Jun;25(2):146-52
pubmed: 20094825
Am J Surg. 2021 Aug;222(2):402-407
pubmed: 33602480
Ann Epidemiol. 2017 Nov;27(11):731-738.e1
pubmed: 29173578
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Cancer. 2017 Dec 15;123 Suppl 24:5014-5036
pubmed: 29205304
World J Gastroenterol. 2014 Jan 28;20(4):869-76
pubmed: 24574761
Cancer. 2010 Oct 1;116(19):4622-31
pubmed: 20626015
Updates Surg. 2019 Sep;71(3):523-531
pubmed: 30788664
Am J Public Health. 2010 Oct;100(10):1912-6
pubmed: 20724684
J Urol. 2013 Feb;189(2):514-20
pubmed: 23253307
JAMA Netw Open. 2020 Jan 3;3(1):e1918911
pubmed: 31922557
Ethn Dis. 2013 Summer;23(3):343-8
pubmed: 23914421
Am J Gastroenterol. 2015 Oct;110(10):1388-94
pubmed: 25964227
J Natl Med Assoc. 2010 Apr;102(4):303-11
pubmed: 20437737
Curr Opin Cardiol. 2021 May 1;36(3):335-339
pubmed: 33769383
J Cancer Educ. 2018 Aug;33(4):757-768
pubmed: 28378200
J Clin Oncol. 2012 Feb 1;30(4):401-5
pubmed: 22184373
Br J Gen Pract. 2020 Jun 25;70(696):e463-e471
pubmed: 32540874
Am J Prev Med. 2016 Dec;51(6):e155-e163
pubmed: 27476382
Ethn Health. 2011 Dec;16(6):501-18
pubmed: 22050536
J Racial Ethn Health Disparities. 2018 Dec;5(6):1346-1353
pubmed: 29603075
N Engl J Med. 2000 Jul 13;343(2):78-85
pubmed: 10891514
J Natl Compr Canc Netw. 2021 Mar 02;19(3):329-359
pubmed: 33724754
J Community Med Health Educ. 2013 Jan 25;3:
pubmed: 24244894
JAMA. 2011 Sep 7;306(9):942-51
pubmed: 21900134
J Health Serv Res Policy. 2012 Apr;17(2):110-8
pubmed: 22008712
Medicine (Baltimore). 2008 Jan;87(1):1-9
pubmed: 18204365
Cancer. 2006 Jul 1;107(1):184-92
pubmed: 16721803
Laryngoscope. 2019 Mar;129(3):643-654
pubmed: 30152118
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4296-301
pubmed: 27044069
Asia Pac J Clin Oncol. 2020 Aug;16(4):193-200
pubmed: 32129941
Eur J Cancer Care (Engl). 2017 Jan;26(1):
pubmed: 27515153
Ethn Dis. 2013 Summer;23(3):349-55
pubmed: 23914422
Cancer Causes Control. 2014 Apr;25(4):419-23
pubmed: 24445597
J Womens Health (Larchmt). 2020 Sep;29(9):1192-1202
pubmed: 32096681
J Stroke Cerebrovasc Dis. 2013 Oct;22(7):e136-41
pubmed: 23219014
Gut. 2021 Dec;70(12):2321-2329
pubmed: 33495268
J Surg Oncol. 2014 Jun;109(7):629-30
pubmed: 24464362
Cancer Causes Control. 2016 Aug;27(8):989-98
pubmed: 27372292
J Med Ethics. 2006 Jun;32(6):346-50
pubmed: 16731734
J Psychosoc Oncol. 2008;26(2):63-86
pubmed: 18285301
Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):3-12
pubmed: 33144285
Surg Endosc. 2020 Jun;34(6):2651-2656
pubmed: 31372887
Ethn Dis. 2013 Winter;23(1):29-34
pubmed: 23495619
Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):384-391
pubmed: 30333221
Am J Public Health. 1997 Nov;87(11):1773-8
pubmed: 9366634
Eur J Surg Oncol. 2018 Oct;44(10):1479-1485
pubmed: 30251641
Cancer Causes Control. 2012 May;23(5):691-702
pubmed: 22460700
Dis Colon Rectum. 2017 Dec;60(12):1241-1249
pubmed: 29112559
J Gen Intern Med. 2003 Dec;18(12):1028-35
pubmed: 14687262
Ann Surg Oncol. 2014 Nov;21(12):3909-16
pubmed: 24849522
JAMA Surg. 2013 Aug;148(8):747-54
pubmed: 23784448
Cancer Med. 2015 Dec;4(12):1863-70
pubmed: 26471963
J Community Health. 2017 Aug;42(4):724-729
pubmed: 28040840
Teach Learn Med. 2022 Jun-Jul;34(3):238-245
pubmed: 33934678
JAMA Netw Open. 2020 Jan 03;3(1):e1920010
pubmed: 31995215
JAMA Netw Open. 2020 Sep 1;3(9):e2016019
pubmed: 32902648

Auteurs

Anya L Greenberg (AL)

Department of Surgery, University of California San Francisco, 550 16Th Street, 6Th Floor, San Francisco, CA, 94158, USA.

Nathan R Brand (NR)

Department of Surgery, University of California San Francisco, 550 16Th Street, 6Th Floor, San Francisco, CA, 94158, USA.

Alan Zambeli-Ljepović (A)

Department of Surgery, University of California San Francisco, 550 16Th Street, 6Th Floor, San Francisco, CA, 94158, USA.

Katherine E Barnes (KE)

Department of Surgery, University of California San Francisco, 550 16Th Street, 6Th Floor, San Francisco, CA, 94158, USA.

Sy Han Chiou (SH)

Department of Surgery, University of California San Francisco, 550 16Th Street, 6Th Floor, San Francisco, CA, 94158, USA.

Kim F Rhoads (KF)

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

Mohamed A Adam (MA)

Department of Surgery, University of California San Francisco, 550 16Th Street, 6Th Floor, San Francisco, CA, 94158, USA.

Ankit Sarin (A)

Department of Surgery, University of California San Francisco, 550 16Th Street, 6Th Floor, San Francisco, CA, 94158, USA. axsarin@ucdavis.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH